Vanessa Cecchin, Maria Elisabetta Zannin, Daniele Ferrari, Irene Pontikaki, Elisabetta Miserocchi, Maria P Paroli, Claudia Bracaglia, Denise Pires Marafon, Serena Pastore, Fulvio Parentin, Gabriele Simonini, Cinzia De Libero, Fernanda Falcini, Antonella Petaccia, Giovanni Filocamo, Riccardo De Marco, Francesco La Torre, Silvana Guerriero, Silvana Martino, Francesco Comacchio, Valentina Muratore, Giorgia Martini, Fabio Vittadello, Francesco Zulian
OBJECTIVE: Anti-TNF-α agents have significantly changed the management of juvenile idiopathic arthritis (JIA). We evaluated the safety and efficacy of adalimumab (ADA) and infliximab (IFX) for the treatment of JIA-associated uveitis in patients treated for ≥ 2 years. METHODS: Patients with JIA-associated uveitis treated with IFX and ADA were managed by a standardized protocol and data were entered in the ORCHIDEA registry. At baseline, all patients were refractory to standard immunosuppressive treatment or were corticosteroid-dependent...
April 15, 2018: Journal of Rheumatology